Dual GIP and GLP-1 receptor agonist
Tirzepatide
An approved dual GIP and GLP-1 receptor agonist marketed under two brand names. Sequence and modification details are stated directly in the FDA-approved labelling.
Also listed as: Mounjaro, Zepbound, LY3298176
Chemical identity
- Compound class
- Dual GIP and GLP-1 receptor agonist
- Sequence
- 39-residue GIP-based analogue with Aib at positions 2 and 13, a C-terminal amide, and Lys20 attached to eicosanedioic acid via a linker
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.53 Da (FDA label); 4813 g/mol (PubChem)
- CAS number
- 2023788-19-2
- PubChem CID
- 156588324
- Research categories
- Incretin analogues, Approved drug substances
United States regulatory status
FDA-approved drug substance
NDA 215866 (Mounjaro), NDA 217806 (Zepbound)
Marketed in the United States as two approved prescription products: Mounjaro (type 2 diabetes mellitus) and Zepbound (chronic weight management).
- Approved prescription drug substance. Mounjaro approved 13 May 2022; Zepbound 8 November 2023.
- Not placed in FDA's Category 2 of bulk substances that may present significant safety risks.
- FDA proposed in April 2026 to exclude tirzepatide from the 503B bulks list.
Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.
Sources
- PubChem CID 156588324
- Drugs@FDA — approved drug products
- FDA — Mounjaro prescribing informationSection 11 (Description) states the sequence modifications and molecular weight.
Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built